No Picture
Trading Ideas

Ford Board Leaves Embattled CEO With Little Room for Error

(Bloomberg) — A little executive bloodletting can sometimes ease the pressure on an embattled chief executive officer. But Jim Hackett is unlikely to see any letup from Ford Motor Co.’s board following the surprise early retirement of one his two top lieutenants.Joe Hinrichs, Ford’s 53-year-old automotive president, will leave on March 1 after almost two decades with the company. As a rising star under celebrated former CEO Alan Mulally, he was put on the fast track to be a potential heir to the top job.With Hinrichs out of the picture, Ford is elevating Jim Farley, the company’s only other president, …read more […]

No Picture
Trading Ideas

JPMorgan: These 3 Stocks Are Well-Positioned to Benefit from 5G Ramp

Investment bank JPMorgan has been looking into the advent of 5G, and pointing out possible paths that the new technology will take as it makes inroads to the digital ecosystem. The most obvious point, of course, is that by the end of this year all of the major mobile providers will have rolled out nationwide 5G networks. That shift has already begun.What is equally important, but less obvious, is that paths toward monetization are not completely clear. JPMorgan does not expect digital customers to pay for 5G specifically in selecting new plans. Customer choice of provider may hinge on the …read more […]

No Picture
Trading Ideas

Bayer asks California court to reverse $86 mln Roundup cancer verdict

Bayer AG has asked a California appeals court to overturn an $86 million verdict that found it was responsible for a couple’s cancer caused by its glyphosate-based weed killer Roundup. In a Friday night filing with the California First District Court of Appeal in San Francisco, the company said the jury’s verdict could not be reconciled with either the law or sound science. The May verdict by a California jury drew nationwide attention for its massive damages, with the jury awarding more than $2 billion to Alberta and Alva Pilliod, who sprayed Roundup on their property for more …read more […]

No Picture
Trading Ideas

Roche, Lilly drugs fail to halt gene-driven Alzheimer's disease

Experimental drugs from Roche and Eli Lilly failed to halt Alzheimer’s disease in their latest test, the companies said on Monday, in a blow to people whose genes make them particularly vulnerable to the illness. Pursuit of an Alzheimer’s remedy, which would inevitably reap drugmakers billions of dollars, has been marked by more than 100 failures, although researchers still hope to tame a condition that affects nearly 6 million Americans, more than 40 million people worldwide, and which is growing more prevalent. The study of Roche’s gantenerumab and Eli Lilly’s solanezumab spearheaded by Washington University in St. Louis …read more […]